These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 17890266

  • 1. Sirolimus in renal transplantation.
    Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, Schmidt J, Zeier M.
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
    [Abstract] [Full Text] [Related]

  • 2. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C.
    Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
    [Abstract] [Full Text] [Related]

  • 3. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
    Mártinez JM, Pulido LB, Bellido CB, Usero DD, Aguilar LT, Moreno JL, Artacho GS, Díez-Canedo JS, Gómez LM, Bravo MA.
    Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
    [Abstract] [Full Text] [Related]

  • 4. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
    Wali RK, Weir MR.
    Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
    [Abstract] [Full Text] [Related]

  • 5. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.
    Alamo JM, Barrera L, Casado MD, Bernal C, Marin LM, Suarez G, Sanchez-Moreno L, Jimenez R, Suarez-Grau JM, Sousa JM, Cordero E, Gomez-Bravo MA.
    Transplant Proc; 2009 Dec; 41(6):2181-3. PubMed ID: 19715866
    [Abstract] [Full Text] [Related]

  • 6. The role and value of sirolimus administration in kidney and liver transplantation.
    Mehrabi A, Fonouni H, Kashfi A, Schmied BM, Morath Ch, Sadeghi M, Schemmer P, Encke J, Sauer P, Zeier M, Weitz J, Büchler MW, Schmidt J.
    Clin Transplant; 2006 Dec; 20 Suppl 17():30-43. PubMed ID: 17100699
    [Abstract] [Full Text] [Related]

  • 7. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 8. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
    Cowan PA, Heizer KE.
    Nephrol Nurs J; 2000 Dec; 27(6):623-5. PubMed ID: 16649344
    [Abstract] [Full Text] [Related]

  • 9. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C.
    Pediatr Transplant; 2006 Aug; 10(5):565-9. PubMed ID: 16856992
    [Abstract] [Full Text] [Related]

  • 10. mToR inhibitors-induced proteinuria: mechanisms, significance, and management.
    Letavernier E, Legendre C.
    Transplant Rev (Orlando); 2008 Apr; 22(2):125-30. PubMed ID: 18631865
    [Abstract] [Full Text] [Related]

  • 11. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ, Elliott EN, Knight RJ, Gaber LW, Gaber AO.
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [Abstract] [Full Text] [Related]

  • 12. The evolving experience using everolimus in clinical transplantation.
    Formica RN, Lorber KM, Friedman AL, Bia MJ, Lakkis F, Smith JD, Lorber MI.
    Transplant Proc; 2004 Mar; 36(2 Suppl):495S-499S. PubMed ID: 15041395
    [Abstract] [Full Text] [Related]

  • 13. Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation.
    Campistol JM, Cockwell P, Diekmann F, Donati D, Guirado L, Herlenius G, Mousa D, Pratschke J, San Millán JC.
    Transpl Int; 2009 Jul; 22(7):681-7. PubMed ID: 19386082
    [Abstract] [Full Text] [Related]

  • 14. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
    Campistol JM, Grinyó JM.
    Transplantation; 2001 Jun 15; 71(11 Suppl):SS42-51. PubMed ID: 11583488
    [Abstract] [Full Text] [Related]

  • 15. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.
    Transplant Proc; 2010 Oct 15; 42(8):3050-2. PubMed ID: 20970607
    [Abstract] [Full Text] [Related]

  • 16. Rejection episodes and 3-year graft survival under sirolimus and tacrolimus treatment after adult intestinal transplantation.
    Lauro A, Dazzi A, Ercolani G, Zanfi C, Golfieri L, Amaduzzi A, Cucchetti A, La Barba G, Grazi GL, D'Errico A, Vivarelli M, Cescon M, Varotti G, Del Gaudio M, Ravaioli M, Di Simone M, Faenza S, Pironi L, Pinna AD.
    Transplant Proc; 2007 Jun 15; 39(5):1629-31. PubMed ID: 17580204
    [Abstract] [Full Text] [Related]

  • 17. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview.
    Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing L.
    Transpl Int; 2007 Apr 15; 20(4):305-11. PubMed ID: 17326771
    [Abstract] [Full Text] [Related]

  • 18. [Low-toxicity immunosuppressive therapy in renal transplant].
    Scolari F, La Manna G, Comai G, Cappuccilli ML, Todeschini P, Ciavatti A, Persici E, Feliciangeli G, Stefoni S.
    G Ital Nefrol; 2007 Apr 15; 24 Suppl 38():44-8. PubMed ID: 17922447
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
    Rodríguez-Moreno A, Ridao N, García-Ledesma P, Calvo N, Pérez-Flores I, Marques M, Barrientos A, Sánchez-Fructuoso AI.
    Transplant Proc; 2009 Apr 15; 41(6):2163-5. PubMed ID: 19715862
    [Abstract] [Full Text] [Related]

  • 20. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
    Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.